WEB NEWS Comments & Business Outlook
MT. KISCO, N.Y., Aug. 14, 2014 (GLOBE NEWSWIRE ) -- ImmuDyne, Inc. (OTCQB:IMMD) announced today that it has entered into a definitive agreement with the Sedona Institute For Age Management, LLC an affiliate of the Sedona Integrative Medical Clinic, LLC, www.sedonaclinic.com, to complete a clinical study on a new application of the company's patented beta glucan technology.
The study will focus on a medical syndrome, which according to a mounting tide of scientific research is having a debilitating effect on the health and vitality of a large segment of our aging population. It is expected that the study will prove that the Company's beta glucan technology can impact this syndrome by modulating the human body's innate immune system. As many as 80 million people in the U.S. and one billion worldwide are affected.
Under the terms of the agreement, ImmuDyne will pay for the beta glucan products to be administered in this study and the blood tests necessary to measure changes in certain biomarkers. The Sedona Integrative Medical Clinic will perform all testing drawing on their 2,000 patient base for participants in the study.
The Sedona Institute for Age Management will supervise the study, develop the application and assist the Company in marketing and establishing new distribution channels for both the application under study as well as existing applications. The Sedona Institute will be compensated with shares of the Company's restricted stock for developing the application and performing the clinical study. They will also earn commissions on sales originated by the Institute.
Eric Haggard, a principal in both the Sedona Clinic and Sedona Institute stated, "This could be a game changer for ImmuDyne. We expect this important study to prove that ImmuDyne's patented beta glucan products will provide significant relief to these people and open the Company to a major new revenue stream."
Joeseph V. DiTrolio, M.D., ImmuDyne's U.S. Chief Medical Officer pointed out, "Sedona Institute is an exceptional opportunity for ImmuDyne to gain market share and patient data documentation for maximum benefit to our clients."
Mark McLaughlin, ImmuDyne's CEO, added, "This is a shareholder friendly, performance based opportunity which gives ImmuDyne the platform to generate this new data, and revenues. Moreover, we are actively pursuing other potential opportunities through which to market our products and increase sales."
Comments & Business Outlook
FORM 10-K For the fiscal year ended December 31, 2013
Immudyne, Inc.
Statement of Operations
Year Ended
December 31
2013
2012
Sales
$ 808,363 $ 673,778
Cost of sales
181,304 199,908
Gross Profit
627,059 473,870
Compensation and related expenses
(651,699 ) (321,263 )
Professional fees
(128,329 ) (253,407 )
General and administrative expenses
(393,439 ) (439,225 )
Operating (Loss)
(546,408 ) (540,025 )
Legal settlement proceeds
210,000 -
License Fee
50,000 25,000
Other income
4,331 55,547
Interest (expense)
(3,385 ) (3,371 )
Net (Loss) Before Taxes
(285,462 ) (462,849 )
Deferred income tax benefit
17,200 17,200
Net (Loss)
$ (268,262 ) $ (445,649 )
Basic and diluted (loss) per share
$ (0.01 ) $ (0.02 )
Average number of common shares outstanding
29,375,000 27,523,000
The accompanying notes are an integral part of these financial statements
Comments & Business Outlook
Immudyne, Inc.
Statement of Operations
(unaudited)
Three Months Ended
Nine Months Ended
2013
2012
2013
2012
Sales
$
94,676
$
152,115
$
647,837
$
558,218
Cost of sales
17,475
53,854
124,181
190,778
Gross Profit
77,201
98,261
523,656
367,440
Compensation and related expenses
(102,166)
(104,668)
(380,154)
(329,641)
Professional fees
(20,129)
(71,827)
(104,157)
(175,344)
General and administrative expenses
(123,572)
(85,406)
(298,953)
(277,630)
Operating (Loss)
(168,666)
(163,641)
(259,608)
(415,175)
License Fee
25,000
-
50,000
25,000
Other income
-
-
-
6,161
Interest (expense)
-
-
-
(3,371)
Net (Loss) Before Taxes
(143,666)
(163,641)
(209,608)
(387,385)
Deferred income tax benefit
4,300
4,300
12,900
12,900
Net (Loss)
$
(139,366)
$
(159,341)
$
(196,708)
$
(374,485)
Basic and diluted (loss) per share
$
(0.00)
$
(0.01)
$
(0.01)
$
(0.01)
Average number of common shares outstanding
29,410,000
28,890,500
29,194.500
27,061,000
Comments & Business Outlook
MT. KISCO, N.Y., June 27, 2013 (GLOBE NEWSWIRE ) -- ImmuDyne, Inc. (OTCQB:IMMD) announced today that the Company is launching an investor awareness campaign beginning on July 9, 2013 and continuing throughout 2013. The Company will be implementing strategies and tactics designed to increase market awareness of ImmuDyne and its product portfolio, among strategic investors, institutions and analysts.
Mark McLaughlin, President and CEO, stated: "We are initiating an IR campaign as one of several steps we will be taking to foster company growth and increase shareholder awareness . During recent months significant progress has been made in identifying strategic partners and distribution channels for our product lines."
Karen Kingston, Chief Marketing Officer, stated: "I am pleased with the consumer and industry response we have received to our new product lines and branding, specifically Primed For Immunity™ (PFI™). We recently held our first PFI Experience Event with Kandy Magazine in Hollywood at the Drais on June 14, 2013. The PFI product, branding, and messaging were received with excitement and enthusiasm. Strong interest was expressed in establishing a strategic partnership from a potential distribution partner and in setting up a US and global network for the PFI product. We will be holding several other events in the Hollywood area this summer to increase demand of this breakthrough product. However, the big picture is the science behind our flagship beta 1/3,1/6 d-glucan product, PURACERE™. We will continue to educate consumers and strategic partners about the critical responsibilities of the immune system and how PURACERE's proprietary beta 1/3,1/6 d-glucan formulation naturally primes the immune system. Notably, the immune system is crucial in regulating the body's energy, weight, inflammation, skin, and even mood. As ImmuDyne continues to move forward with our business plan, PURACERE's applications across dozens of multi-billion dollar therapeutic and wellness markets will become more evident."
